Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis
Stephen W Mamber, Thomas Hatch, Craig S Miller, John V Murray, Cynthia Strout, John McMichael, Stephen W Mamber, Thomas Hatch, Craig S Miller, John V Murray, Cynthia Strout, John McMichael
Abstract
Background: Thimerosal (TML) is an organomercury antimicrobial. Low doses (1/250th of the amount in a typical vaccine dose) may promote an antiviral immune response. Low-dose TML (BTL-TML) was evaluated for safety and efficacy against herpes labialis in two FDA-approved, randomized, double blind, placebo-controlled clinical trials.
Methods: BTL-TML was evaluated in a Phase IIa trial for its ability to block progression to lesion in subjects with recurrent oral herpes caused by dental trauma. Subjects were administered BTL-TML or a saline control over a 7-day period. In a Phase IIb trial, BTL-TML was evaluated for its ability to block progression to lesion over a 7-day period in subjects with herpes lip infections induced by exposure to ultraviolet (UV) radiation.
Results: Progression to lesion post-dental procedure was prevented in 54.5% (12/22) TML subjects versus 22.2% (2/9) control subjects (p = 0.106). Progression to lesion post-UV irradiation was blocked in 47.8% (11/23) BTL-TML treatment subjects and 42.8% (6/14) control subjects. A post-hoc analysis yielded 52.2% (12/23) BTL-TML subjects with no progression to lesion versus 28.6% (6/21) control subjects with no progression (p = 0.099). There were no significant differences in adverse effects between treatment and control groups in either trial.
Conclusions: Neither clinical trial showed a statistically significant effect of BTL-TML on progression to lesion. However, the post-hoc analysis suggested there is a 48-hour period following UV radiation exposure during which the anti-herpes activity of antivirals such as BTL-TML is reduced. Accordingly, BTL-TML may have promise in subsequent, properly designed and powered clinical trials.
Trial registration: ClinicalTrials.gov NCT01308424 NCT01902303.
Keywords: HSV1; cold sores; herpes simplex labialis; oral herpes; oral treatment; thimerosal.
Conflict of interest statement
Declaration of Conflicting Interests: Hatch and McMichael are employees of Beech Tree Labs, the sponsor of both the P2a and P2b studies.
Figures
References
- Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Semin Dermatol. 1992 Sep;11(3):200-206. PMID: 1390034.
- Fatahzadeh M, Schwartz RA. Human herpes simplex labialis. Clin Exp Dermatol. 2007 Nov;32(6):625-630. doi: 10.1111/j.1365-2230.2007.02473.x. PMID: 17953630.
- Patel AR, Romanelli P, Roberts B, Kirsner RS. Treatment of herpes simplex virus infection: rationale for occlusion. Adv Skin Wound Care. 2007 Jul;20(7):408-412. doi: 10.1097/01.ASW.0000280199.58260.62. PMID: 17620742.
- Petti S, Lodi G. The controversial natural history of oral herpes simplex virus type 1 infection. Oral Dis. 2019 Nov;25(8):1850-1865. doi: 10.1111/odi.13234. Epub 2019 Nov 27. PMID: 31733122.
- Gilbert S, Corey L, Cunningham Aet al. et al. An update on short-course intermittent and prevention therapies for herpes labialis. Herpes. 2007 Jun;14(Suppl 1):13A-18A. PMID: 17877887.
- Marques-Silva L, Castro WH, Gomez EL, Guimarães AL, Silva MS, Gomez RS. The impact of dental surgery on HSV-1 reactivation in the oral mucosa of seropositive patients. J Oral Maxillofac Surg. 2007 Nov;65(11):2269-2272. doi: 10.1016/j.joms.2007.05.029. PMID: 17954324.
- Spruance SL, Kriesel JD, Evans TG, McKeough MB. Susceptibility to herpes labialis following multiple experimental exposures to ultraviolet radiation. Antiviral Res. 1995 Sep;28(1):57-67. doi: 10.1016/0166-3542(95)00038-n. PMID: 8585760.
- Hull CM, Levin MJ, Tyring SK, Spruance SL. Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis. Antimicrob Agents Chemother. 2014;58(3):1273-1278. doi: 10.1128/AAC.02150-13. Epub 2013 Dec 16. PMID: 24342632; PMCID: PMC3957859.
- Cunningham A, Griffiths P, Leone Pet al. et al. Current management and recommendations for access to antiviral therapy of herpes labialis. J Clin Virol. 2012 Jan;53(1):6-11. doi: 10.1016/j.jcv.2011.08.003. Epub 2011 Sep 1. PMID: 21889905; PMCID: PMC3423903.
- James C, Harfouche M, Welton NJet al. et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020 May 1;98(5):315-329. doi: 10.2471/BLT.19.237149. Epub 2020 Mar 25. PMID: 32514197; PMCID: PMC7265941.
- Raborn GW, Grace MG. Recurrent herpes simplex labialis: selected therapeutic options. J Can Dent Assoc. 2003 Sep;69(8):498-503. PMID: 12954137.
- Harmenberg J, Oberg B, Spruance S. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: a literature review. Acta Derm Venereol. 2010 Mar;90(2):122-130. doi: 10.2340/00015555-0806. PMID: 20169294.
- Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes. 2002 Dec;9(3):64-69. PMID: 12470603.
- Usatine RP, Tinitigan R. Nongenital herpes simplex virus. Am Fam Physician. 2010 Nov 1;82(9):1075-1082. PMID: 21121552.
- Leung AKC, Barankin B. Herpes labialis: an update. Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):107-113. doi: 10.2174/1872213X11666171003151717. PMID: 28971780.
- Sacks SL, Thisted RA, Jones TMet al. Docosanol 10% Cream Study Group. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001 Aug;45(2):222-230. doi: 10.1067/mjd.2001.116215. PMID: 11464183.
- Opstelten W, Neven AK, Eekhof J. Treatment and prevention of herpes labialis. Can Fam Physician. 2008 Dec;54(12):1683-1687. PMID: 19074705; PMCID: PMC2602638.
- Pless R, Risher JF. Mercury, infant neurodevelopment, and vaccination. J Pediatr. 2000 May;136(5):571-573. doi: 10.1067/mpd.2000.106797. PMID: 10802484.
- Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001 May;107(5):1147-1154. doi: 10.1542/peds.107.5.1147. PMID: 11331700.
- Clarkson TW. The three modern faces of mercury. Environ Health Perspect. 2002 Feb;110 Suppl 1(Suppl 1):11-23. doi: 10.1289/ehp.02110s111. PMID: 11834460; PMCID: PMC1241144.
- FDA Thimerosal in vaccines. .
- Miller JB. Treatment of active herpes virus infections with influenza virus vaccine. Ann Allergy. 1979 May;42(5):295-305. PMID: 453646.
- McMichael J. 2001, Jan 16. Methods for treating herpes virus infections. US patent 6,174,916.
- Loison E, Poirier-Beaudouin B, Seffer Vet al. et al. Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells. PLoS One. 2014 Apr 1;9(4):e92705.
- Mei XX, Lei SS, Xu Let al. et al. Herpes simplex virus type I-infected disorders alter the balance between treg and Th17 cells in recurrent herpes labialis patients. Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420933099. doi: 10.1177/2058738420933099. PMID: 32735468; PMCID: PMC7401041.
- Miller CS, Cunningham LL, Lindroth JE, Avdiushko SA. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures. J Am Dent Assoc. 2004 Sep;135(9):1311-1318. doi: 10.14219/jada.archive.2004.0407. PMID: 15493396.
- Spruance SL. Pathogenesis of herpes simplex labialis: experimental induction of lesions with UV light. J Clin Microbiol. 1985 Sep;22(3):366-368. doi: 10.1128/jcm.22.3.366-368.1985. PMID: 2995436; PMCID: PMC268411.
- Sayre RM, Dowdy JC, Harris KA, Berg JE, Trimble MW. A practical UV source to induce herpes simplex labialis lesions in the clinic. Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):20-23. doi: 10.1111/j.1600-0781.2007.00266.x. PMID: 17254031.
- Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis. 1999 Feb;179(2):303-310. doi: 10.1086/314605. PMID: 9878012.
- Hull C, McKeough M, Sebastian K, Kriesel J, Spruance S. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009 Mar;23(3):263-267. doi: 10.1111/j.1468-3083.2008.03047.x. Epub 2009 Jan 8. PMID: 19143902.
- Spruance SL, Jones TM, Blatter MMet al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother. 2003 Mar;47(3):1072-1080. doi: 10.1128/AAC.47.3.1072-1080.2003. PMID: 12604544; PMCID: PMC149313.
- Bieber T, Chosidow O, Bodsworth Net al. LIP Study Group. Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014 Jul;13(7):791-798. PMID: 25007361.
- Hull CM, Harmenberg J, Arlander Eet al. et al. ME-609 Study Group. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011 Apr;64(4):696.e1-11. doi: 10.1016/j.jaad.2010.08.012. Epub 2010 Sep 20. PMID: 20851499.
Source: PubMed